Klaus Klumpp
Research Subjects
Klaus Klumpp has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Andrea Wolkerstorfer
Hoffmann-La Roche Inc., Virology Discovery, Nutley, NJ 07110, USA, 2Savira pharmaceuticals GmbH, Veterinaerplatz 1/IA, A-1210, Vienna, Austria, 3European Molecular Biology Laboratory, Grenoble Outstation, 6 rue Jules Horowitz, BP181, 38042 Grenoble Cedex 9, France, 4Unit of Virus Host Cell Interactions, University Grenoble Alpes-EMBL-CNRS, 6 rue Jules Horowitz, BP181, 38042 Grenoble Cedex 9, France and 5RiboScience LLC, 3901 Laguna Avenue, Palo Alto, CA 94306, USA
1 shared publicationAngela M. Lam
Novira Therapeutics Inc, part of the Janssen Pharmaceutical Companies, Doylestown, Pennsylvania
1 shared publication- Anne E. Geller
Department of Microbiology and Immunology and
1 shared publication - Daniel Obrecht
Spexis AG, Hegenheimermattweg 125, CH-4112 Allschwil, Switzerland
1 shared publication - David K. Meyerholz
Department of Pathology, University of Iowa
1 shared publication - Divyasha Saxena
Center for Predictive Medicine, School of Medicine, University of Louisville, Louisville, KY 40202, USA
1 shared publication
Latest Publications
- Open Access
- 31 December 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (4)
CXCL12 ameliorates neutrophilia and disease severity in SARS-CoV-2 infection
Neutrophils, particularly low-density neutrophils (LDNs), are believed to contribute to acute COVID-19 severity. Here, we showed that neutrophilia can be detected acutely and even months after SARS-CoV-2 infection in patients and mice, while neutrophil depletion reduced disease severity in mice. A key factor in neutrophilia and severe disease in infected mice was traced to the chemokine CXCL12 secreted by bone marrow cells and unexpectedly, endothelial cells. CXCL12 levels were negatively correlated with LDN numbers in longitudinal analyses of patient blood samples. CXCL12 blockade in SARS-CoV-2–infected mice increased blood/lung neutrophil numbers, thereby accelerating disease progression without changing lung virus titers. The exaggerated mortality caused by CXCL12 blockade could be reversed by neutrophil depletion. In addition, blocking interactions between SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2) reduced CXCL12 levels, suggesting a signal transduction from virus-mediated ACE2 ligation to increased CXCL12 secretion. Collectively, these results demonstrate a previously unappreciated role of CXCL12 in diminishing neutrophilia, including low-density neutrophilia, and its deleterious effects in SARS-CoV-2 infections. The results also support the involvement of SARS-CoV-2–endothelial cell interactions in viral pathogenesis.
- 31 December 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (4)
Open AccessCXCL12 ameliorates neutrophilia and disease severity in SARS-CoV-2 infection
Neutrophils, particularly low-density neutrophils (LDNs), are believed to contribute to acute COVID-19 severity. Here, we showed that neutrophilia can be detected acutely and even months after SARS-CoV-2 infection in patients and mice, while neutrophil depletion reduced disease severity in mice. A key factor in neutrophilia and severe disease in infected mice was traced to the chemokine CXCL12 secreted by bone marrow cells and unexpectedly, endothelial cells. CXCL12 levels were negatively correlated with LDN numbers in longitudinal analyses of patient blood samples. CXCL12 blockade in SARS-CoV-2–infected mice increased blood/lung neutrophil numbers, thereby accelerating disease progression without changing lung virus titers. The exaggerated mortality caused by CXCL12 blockade could be reversed by neutrophil depletion. In addition, blocking interactions between SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2) reduced CXCL12 levels, suggesting a signal transduction from virus-mediated ACE2 ligation to increased CXCL12 secretion. Collectively, these results demonstrate a previously unappreciated role of CXCL12 in diminishing neutrophilia, including low-density neutrophilia, and its deleterious effects in SARS-CoV-2 infections. The results also support the involvement of SARS-CoV-2–endothelial cell interactions in viral pathogenesis.
- 1 February 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (3) , 652-662.e8
Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection
- 1 February 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (3) , 652-662.e8
Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection
- Open Access
- 11 July 2013
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 41 (17) , 8289-8299
Characterization of PA-N terminal domain of Influenza A polymerase reveals sequence specific RNA cleavage
Influenza virus uses a unique cap-snatching mechanism characterized by hijacking and cleavage of host capped pre-mRNAs, resulting in short capped RNAs, which are used as primers for viral mRNA synthesis. The PA subunit of influenza polymerase carries the endonuclease activity that catalyzes the host mRNA cleavage reaction. Here, we show that PA is a sequence selective endonuclease with distinct preference to cleave at the 3′ end of a guanine (G) base in RNA. The G specificity is exhibited by the native influenza polymerase complex associated with viral ribonucleoprotein particles and is conferred by an intrinsic G specificity of the isolated PA endonuclease domain PA-Nter. In addition, RNA cleavage site choice by the full polymerase is also guided by cap binding to the PB2 subunit, from which RNA cleavage preferentially occurs at the 12th nt downstream of the cap. However, if a G residue is present in the region of 10–13 nucleotides from the cap, cleavage preferentially occurs at G. This is the first biochemical evidence of influenza polymerase PA showing intrinsic sequence selective endonuclease activity.
- 11 July 2013
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 41 (17) , 8289-8299
Open AccessCharacterization of PA-N terminal domain of Influenza A polymerase reveals sequence specific RNA cleavage
Influenza virus uses a unique cap-snatching mechanism characterized by hijacking and cleavage of host capped pre-mRNAs, resulting in short capped RNAs, which are used as primers for viral mRNA synthesis. The PA subunit of influenza polymerase carries the endonuclease activity that catalyzes the host mRNA cleavage reaction. Here, we show that PA is a sequence selective endonuclease with distinct preference to cleave at the 3′ end of a guanine (G) base in RNA. The G specificity is exhibited by the native influenza polymerase complex associated with viral ribonucleoprotein particles and is conferred by an intrinsic G specificity of the isolated PA endonuclease domain PA-Nter. In addition, RNA cleavage site choice by the full polymerase is also guided by cap binding to the PB2 subunit, from which RNA cleavage preferentially occurs at the 12th nt downstream of the cap. However, if a G residue is present in the region of 10–13 nucleotides from the cap, cleavage preferentially occurs at G. This is the first biochemical evidence of influenza polymerase PA showing intrinsic sequence selective endonuclease activity.
- 20 February 2003
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 46 (7) , 1153-1164
Use of a Pharmacophore Model To Discover a New Class of Influenza Endonuclease Inhibitors
Data from both our own and literature studies of the biochemistry and inhibition of influenza virus endonuclease was combined with data on the mechanism of action and the likely active site mechanism to propose a pharmacophore. The pharmacophore was used to design a novel structural class of inhibitors, some of which were found to have activities similar to that of known influenza endonuclease inhibitors and were also antiviral in cell culture.
- 20 February 2003
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 46 (7) , 1153-1164
Use of a Pharmacophore Model To Discover a New Class of Influenza Endonuclease Inhibitors
Data from both our own and literature studies of the biochemistry and inhibition of influenza virus endonuclease was combined with data on the mechanism of action and the likely active site mechanism to propose a pharmacophore. The pharmacophore was used to design a novel structural class of inhibitors, some of which were found to have activities similar to that of known influenza endonuclease inhibitors and were also antiviral in cell culture.